---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-046096"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:05:30.684507+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics appoints Shannon Campbell and Prakash Raman to board; Dixon and Mayweg resign

## Summary
- Wendy Dixon and Alex Mayweg resigned from board effective April 10, 2024; no disagreement cited.
- Shannon Campbell (EVP/Chief Commercial Officer at Merus) appointed Class III director, will serve on Compensation Committee.
- Prakash Raman (CEO of stealth biopharma) appointed Class I director, will serve on Audit and Nominating/Governance Committees.
- New directors are independent under Nasdaq standards and will receive standard non-employee director compensation.

## SEC filing metadata
- accession: 0001104659-24-046096
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/tm2411574d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-046096
- JSON: https://secwatch.observer/filing/0001104659-24-046096.json
- Plain text: https://secwatch.observer/filing/0001104659-24-046096.txt

## Key facts
- Executive change
  Wendy L. Dixon resigned as Director at Black Diamond Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm
- Executive change
  Prakash Raman was appointed as Director at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm
- Executive change
  Alexander Mayweg resigned as Director at Black Diamond Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.